Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Boston, MA.

ENZYCHEM LIFESCIENCES Corp. engages in developing, manufacturing, and distributing pharmaceutical products. Its main products include beta lactam antibiotics, non-beta lactam active pharmaceutical ingredient (APIs), and others. The beta lactam antibiotics include Cefazedone, Cefbuperazone and Ceftizoxime. The non-beta lactam APIs include D-cycloserine and Talniflumate. The company was founded on July 20, 1999 and is headquartered in Jecheon-si, South Korea.

Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA.

Part of Siemens AG, Siemens Healthcare Diagnostics Products GmbH is a German company located in Marburg that manufactures and supplies healthcare diagnosis and monitoring equipment. It was founded in 1996. J��rg Berner and Michael Heinold are the current co-CEOs of the firm.

Your B2B Partner for Innovation in Health, Wellbeing, Cosmetics and Life Science Over 20 years of experience in the production and use of Ectoin® and other extremolytes makes bitop a valuable and trustworthy partner for the pharmaceutical, cosmetics, and life science industries.

Universiteit Utrecht Holding BV provides portfolio management and commercial development services. It strengthen and broaden cooperation among partners encompassing companies, governmental institutions, cultural and social organizations. The company was founded in 1996 and is headquartered in Utrecht, the Netherlands.

B·R·A·H·M·S explores, develops and produces new diagnostic test procedures to improve the diagnosis, and thereby the treatment, of life-threatening illnesses. This takes place with over 400 employees, on the basis of their own patented biomarkers, and leads to medically and economically superior diagnostic insights for patients and medical professionals. B·R·A·H·M·S products reach customers in over 65 countries around the world and are leaders in their specialized markets.

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Lunan Pharmaceutical Group is an Integrated pharmaceutical group, National innovative enterprise and National torch plan key high-tech enterprise that produces, researches and sells both traditional Chinese medicine, chemical medicine and bio-pharmaceutical medicinal products.

Fuzhou Taijiang District Zeyue Pharmaceutical Technology Co., Ltd., established on 2011-08-23, Business scope includes medical technology consulting,drug development,Medical technology transfer.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment. The company is developing two unique programs such as drug candidate, X4P-001, has clinical experience in over 70 subjects, and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC), the second program, X4P-002, is a unique series of late lead molecules that penetrate the blood-brain barrier. They will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

ProMetic BioSciences Ltd. operates as a biopharmaceutical company. The company was founded by Christopher Robin Low and is headquartered in Laval, Canada.

Part of CSPC Pharmaceutical Group Ltd., CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd. is a company headquartered in China. The firm engages in pharmaceutical research and development.

Nanjing Dayuan Beauty and Health Co., Ltd., established on 1993-05-10, Business scope includes health food production(Restricted Su Food and Drug Health and Health Approval[2011]No.0005range listed);drinks(solid drink)Production;Healthy food,food development;cosmetic,Beauty and health underwear,Cleaning Products,Daily Chemicals,Development of plastic products,Production;Sales of self-produced products and related supporting services,consult,And the import and export of similar goods of the company's own products,wholesale.(The import and export of the above commodities does not involve state trade,Import and Export Quota License,export quota bidding,Specially managed commodities such as export licenses)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Taisho Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following divisions: Self-Medication, Prescription Pharmaceutical and Overseas Development. The Self-Medication division deals with the research, development, and production of over-the-counter (OTC) drugs, medical supplies, food for specific health use, and hygiene products. The Prescription Pharmaceutical division handles research and development of new drugs in the fields of central nervous system diseases, metabolic diseases, infectious diseases, and inflammatory diseases. The Overseas Development division markets energy drinks and OTC pharmaceuticals overseas. The company was founded on October 12, 1912 and is headquartered in Tokyo, Japan.

BAG Health Care GmbH engages in the development, production and distribution of In-vitro diagnostics and indicators for the monitoring of sterilization and disinfection control. It operates through three business segments: Diagnostics, Hygiene Monitoring and Pharmaceutical contract manufacturing. The Diagnostics segment develops and manufactures innovative in-vitro-diagnostics and distributes these internationally.The BAG reagents and in-vitro-diagnostic systems are used in hospitals, blood banks and medical laboratories worldwide. The Hygiene Monitoring segment offers a wide range of products for hygiene monitoring in hospitals, doctors' offices, institutes and the industry. The Pharmaceutical contract manufacturing segment manufactures pharmaceuticals on contract and it specializes in aseptic filling and lyophilisation of parenteralia benefitting from experience in lyophilisation. The company was founded in 1947 and is headquartered in Lich, Germany.